Biorasi Completes Rare Nephrology Trial During COVID-19
Biorasi has completed subject visits under Part A in a rare disease nephropathy study during the peak of the COVID-19 outbreak.
30
06, 2020
18
11, 2019
Mind-Boggling Displays, Industry Trends, & other Highlights from ASN Kidney Week 2019
A team from Biorasi was at ASN Kidney Week 2019. Breakthrough research and standout presentations marked this year’s @ASNKidney Week. Check out our report for the full scoop.
4
09, 2019
Acute Kidney Injury (AKI): Management and Outcome
In my previous article, I explained the types, causes and symptoms of Acute Kidney Injury (AKI). Here, I’ll share how physicians treat and manage AKI, as well as what to expect. CRRT or intermittent hemodialysis? To treat AKI, nephrologists primarily use renal replacement therapy (RRT), which includes intermittent hemodialysis, peritoneal hemodialysis, various forms of CRRT, and “hybrid” therapies such as prolonged intermittent renal replacement therapy (PIRRT) or sustained low-efficiency hemodialysis (SLED). A few clinical trials are taking a look at CRRT and intermittent hemodialysis under different conditions.
27
08, 2019
Acute Kidney Injury (AKI): Why aggressive treatment early is a must
What is AKI? AKI is a sudden, reversible decline in the kidney’s glomerular filtration rate (GFR); in other words, its ability to filter metabolic waste. This kidney damage causes an elevation of serum urea and creatinine, which affects the body's ability to function properly. Most AKI cases are reversible. However, it's important to treat AKI as early as possible to avoid its progression to chronic kidney disease or kidney failure.
17
07, 2019
FSGS: A rare kidney disease without targeted therapies
Researchers are studying a few new and existing drugs to treat FSGS. FSGS needs a novel medication that regulates both high body fats and inflammasome inhibition via upstream innate immune system to block intracellular initiation of inflammatory cascade and extra cellular inflammation. Over the past five years, nearly 30% of Biorasi-initiated or ongoing studies involved chronic kidney disease. Our experience allows us to develop successful nephrology clinical trials.
5
01, 2019
Immuno-Oncology Summit 2019
Biorasi will be attending and exhibiting at the Immuno-Oncology 2019 summit from August 5-9 in Boston, […]
4
01, 2019
ASN Kidney Week 2019
Biorasi will be attending and exhibiting at the Kidney Week 2019 conference from November 5-10 in […]
4
10, 2018
Six Things We Can Do Now to Advance Clinical Research in CKD
The CKD community has set some lofty goals for the coming years. There are hopes to enroll 30% of patients with CKD in a clinical trial by 2030. This is important to create a more substantial research base for CKD.
30
10, 2017
The IgAN Enigma
Immunoglobulin A (IgA) is an antibody manufactured by the body’s immune system to protect against invaders. […]
27
12, 2016
Managing the Complexities of Clinical Trials in the Dialysis-Dependent CKD Population
Ensuring timely, quality, cost-effective execution of ESRD clinical trials requires a research organization to leverage the right people, processes, and technology infrastructure to overcome the trial complexities inherent in ESRD drug development. This white paper explores the complexities of running clinical trials in advanced CKD and the ESRD populations and looks at the solutions that can be employed to overcome challenges.
